Clinical Trials Logo

Cervical Cancer clinical trials

View clinical trials related to Cervical Cancer.

Filter by:

NCT ID: NCT04068675 Completed - Ovarian Cancer Clinical Trials

Effects of Centering Pre-operative Counseling on Patient Reported Anxiety

Start date: February 24, 2020
Phase: N/A
Study type: Interventional

The primary objective of the study is to evaluate the effect of pre-operative counseling in a group setting on patient reported anxiety for patients scheduled to undergo surgery for a known or suspected gynecologic malignancy. Patient reported anxiety will be evaluated using a validated Patient-Reported Outcomes Measurement Information System (PROMIS) survey. We hypothesize that the group counseling session will reduce patient reported anxiety by a clinical meaningful level. Secondary objectives will evaluate the effect of the intervention on patient reported depression levels and compare adherence to Enhanced Recovery After Surgery (ERAS) instructions, utilization of unscheduled health care resources, and anxiety/depression levels to historical controls.

NCT ID: NCT04064515 Completed - Cervical Cancer Clinical Trials

CTCs in Cervix Cancer

Start date: March 2, 2020
Phase:
Study type: Observational

This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.

NCT ID: NCT04000503 Completed - Cervical Cancer Clinical Trials

Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge)

ASPIRE
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this pragmatic cluster randomized control trial is to test the effectiveness of cervical cancer screening follow-up completion using two implementation approaches for self-collected HPV testing in a rural, low-resource setting: 1) community health workers recruiting women door-to-door and 2) community health workers recruiting women at community health meetings. This study will also help to further understand how current patient referral systems are working between health facilities, patient and provider preferences for integrated care and health system related barriers to integrated cervical cancer screening. Hypothesis: More women will receive screening via the community health meeting but the engagement to care (i.e., visual inspection with acetic acid-our main outcome) will be greater in the door-to-door arm.

NCT ID: NCT03985072 Completed - Colorectal Cancer Clinical Trials

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Start date: April 26, 2019
Phase: Phase 1
Study type: Interventional

The study is a Phase 1 Open-label Two-stage, Safety and Tolerability Study with Cancer Type-specific Cohorts, Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Solid Tumors that are Refractory to Standard Therapy or For Which No Standard Therapy Is Available. Patients with unresectable solid tumors that are refractory or have failed standard therapy and are deemed non-eligible or intolerant to further therapy or for which no standard therapy is available will be included in 5 cancer type-specific parallel cohorts. The following tumor types will be evaluated for potential inclusion in each cancer type-specific cohort: gallbladder & biliary tract carcinoma; cervical carcinoma; gastric carcinoma; pancreatic carcinoma, and colorectal carcinoma.

NCT ID: NCT03958357 Completed - Cervical Cancer Clinical Trials

Post Market Clinical Follow-up Study Venezia

Start date: April 10, 2019
Phase:
Study type: Observational

The investigational device is the Advanced Gynecological Applicator (AGA) Venezia configuration, an applicator to treat locally advanced stage cervical cancer. The goal of the study is to assess the performance and the unknown risks or complications of the AGA Venezia configuration during clinical use of the applicator.

NCT ID: NCT03935204 Completed - Cervical Cancer Clinical Trials

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start date: May 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged 18-45 years old.

NCT ID: NCT03873376 Completed - Cervical Cancer Clinical Trials

Self-sampling Among Long-term Non-attenders to Cervical Cancer Screening

Start date: March 11, 2019
Phase: N/A
Study type: Interventional

The trial will evaluate whether human papillomavirus (HPV) self-sampling may increase cervical cancer screening attendance among under-screened women in Norway, how different ways of offering self-sampling and follow-up may affect attendance, and whether self-sampling may reduce inequities in attendance.

NCT ID: NCT03872635 Completed - Anesthesia Clinical Trials

Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

To evaluate the effects of preoperative oral carbohydrate on postoperative insulin resistance and tumor immunity in cervical cancer patients with neoadjuvant chemotherapy.

NCT ID: NCT03856684 Completed - Cervical Cancer Clinical Trials

Evaluation of Three Strategies Based on Vaginal Self-sampling Kit Send to Home of Unscreened Women for Cervical Cancer

APACHE-4
Start date: February 11, 2020
Phase: N/A
Study type: Interventional

Despite the existence of an effective screening test (pap smear), cervical cancer is, every year in France, the cause of more than 3,000 new cases and 1,100 deaths. But, in France, 4 in 10 women are not screened or not often enough (nearly 7 millions women). It is therefore necessary to develop new strategies to reach these women. The etiological factor of this cancer is persistent infection with High-Risk Human PapillomaVirus (HR-HPV). Thereby, HPV-based tests could be alternative screening tests. Vaginal self-sampling with HR-HPV test is simpler and less intrusive than the pap smear. It has been shown that sending vaginal self-sampling kit (with HPV test) to unscreened women's home is a powerful means to increase the participation rate of cervical cancer screening. It seems interesting to explore methods to increase the efficiency of this strategy by optimizing the ratio of the number of kits used compared to the number of kits sent. Two approaches will be tested: a system "available on request" of the kit and / or the addition of an SMS (Short Message Service) reminder.

NCT ID: NCT03856437 Completed - Cervical Cancer Clinical Trials

A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

Start date: January 22, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to determine the effects of message framing (gain vs. loss) on African American parents' acceptance of the HPV vaccine and how such effects are moderated by parents' salient beliefs prior to message exposure. Participants are randomized into gain and loss conditions in which they view either gain-framed or loss-framed HPV vaccination messages. Key outcome variables include parents' attitudes and intentions toward vaccinating their children against HPV.